Full Service Maintenance For PET/CT In-Vivo Animal Imagers

Title: Full Service Maintenance for two (2) multi-scan LFER PET/CT IN-VIVO Animal Imager instruments

• (i) This is a combined for commercial items prepared in accordance with the format in FAR Subpart 12.6, as supplemented with additional information included in this notice. This announcement constitutes the only solicitation; proposals are being requested, and a separate written solicitation will not be issued.
• (ii) The solicitation number is 75N98026Q00669. This solicitation is issued as a Notice of Intent (NOI) for a non-competitive combined to award a contract or purchase order without providing for full and open competition, including Brand Name. This acquisition is conducted under the authority of FAR 12.603, Streamlined Solicitation for Commercial Products or Commercial Services, and is not expected to exceed the simplified acquisition threshold. Additional authority includes 41 U.S.C. 1901 and FAR 6.302-3(a)(2)(ii). The National Institutes of Health (NIH), , intends to negotiate and award a firm-fixed price purchase order on a non-competitive basis to Mediso USA LLC, 1530 Wilson Blvd STE 115, Arlington, VA, 22209-2447 to procure an annual full service maintenance contract for two (2) MultiScan LFER PET/CT IN-VIVO Animal Imager instruments located in Bethesda, MD.
• (iii) The solicitation document and incorporated provisions and clauses are those in effect through Federal Acquisition Circular FAC 2026-01 dated January 2026.
• (iv) The associated North American Industry System (NAICS) code for this procurement is 811210 - Electronic and Precision Equipment Repair and Maintenance, and the small business size standard is $34M. This requirement is not set aside for small business.
• (v) Description of Requirement: The government requires the following brand name services: Instrument: Mediso MultiScan LFER 150 PET/CT Serial Number(s): LF000010-0008V1 and LF000010-0009V1 Service Plan: Mediso Preventative Maintenance and Service Agreement (brand name) Required by the National Institute of Allergy and Infectious Diseases (NIAID), Division of Intramural Research (DIR), Laboratory of Clinical Infectious Diseases (LCID), Tuberculosis Research Section (TRS). In NIAID clinical studies, we are using 18F-fluoro-2-deoxy-D-glucose (FDG) positron emission tomography (PET) and high-resolution computed tomography (HR-CT) imaging to monitor response to chemotherapy in TB patients. The results have re-emphasized that TB in humans is a complex disease, usually presenting with a spectrum of lesions, both structurally and functionally, even within a single patient. The difficulty in the human studies is that we cannot make a direct physical correlation with the images we see by PET/CT and the changes in microbiologic and histopathologic outcome of the individual lesions and overall disease. By adding HR-CT and FDG-PET monitoring to our animal experiments, we can make correlations with the results we are observing in TB patients and provide context for the interpretation of the human results using tractable animal models. In addition, we will test new potential PET probes designed to target features of the bacteria or the disease in animals to determine their usefulness before pursuing the probes use in humans. This project requires regular access to PET/CT imaging equipment with sufficient resolution and speed to image 0.1 mm anatomic structures in animals as big as macaques and adult NZW rabbits located in a NIAID animal BSL-3 facility. The warranty will expire in June 2026, and we must put a new service contract in place for the machine directly with Mediso USA LLC. No other vendor or 3rd party can be accepted as the machine is still new and unique and cannot be serviced by a 3rd party to avoid nulling the remaining warranty features.
• (vi) Delivery Location: National Institute of Health National Institute of Allergy and Infectious Diseases (NIAID) 33 North Drive, BLDG 33 RM 1N19 Bethesda, MD 20892
• (vii) The statutory authority for this sole source requirement is 41 U.S.C. 1901
• (a) (1) as implemented by FAR 13.106-1 only one responsible source and no other supply of service will satisfy agency

requirements. (viii) The provision at FAR 52.212-1,

Instructions to Offerors—Commercial Items, applies to this acquisition. Add any additional instructions as required.

• (ix) The provision at FAR 52.212-2, Evaluation—Commercial Items, applies to this acquisition.
• (a) A written notice of award or acceptance of an offer, issued to the successful offeror within the time specified in the offer, shall result in a binding contract without further action by either party. The Government reserves the right to accept any offer (or part of an offer) before the expiration date, whether or not discussions are conducted, unless a written notice of withdrawal is received prior to award. Add additional

evaluation criteria as required.